Hangzhou Shuoxi Bio-pharmaceutical

Hangzhou Shuoxi Bio-pharmaceutical is a clinical-stage biotechnology company based in China, specializing in the discovery and development of innovative small molecule therapeutics for metabolic diseases and chronic conditions. The company leverages a proprietary structure-based drug design (SBDD) platform to create highly potent and selective oral treatments, with a primary focus on the incretin pathway. Its lead candidate, SX-001, is an orally bioavailable, non-peptide GLP-1 receptor agonist currently being evaluated in Phase 1 clinical trials for the treatment of type 2 diabetes and obesity. Shuoxi aims to address significant unmet medical needs by providing more convenient and effective oral alternatives to traditional injectable biologics. The company is backed by top-tier venture capital firms and maintains a robust pipeline of multi-target small molecules.